2001
Tamoxifen and Cardiac Risk Factors in Healthy Women
Cushman M, Costantino J, Tracy R, Song K, Buckley L, Roberts J, Krag D. Tamoxifen and Cardiac Risk Factors in Healthy Women. Arteriosclerosis Thrombosis And Vascular Biology 2001, 21: 255-261. PMID: 11156862, DOI: 10.1161/01.atv.21.2.255.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnti-Inflammatory AgentsAntineoplastic Agents, HormonalBlood CoagulationBreast NeoplasmsCardiovascular DiseasesCardiovascular SystemCholesterolC-Reactive ProteinDouble-Blind MethodFemaleFibrinogenHumansPlacebosPostmenopauseRisk FactorsSelective Estrogen Receptor ModulatorsTamoxifenConceptsEffects of tamoxifenBreast Cancer Prevention TrialIncidence of breast cancerCardiovascular disease risk factorsHigh waist-to-hip ratioWaist-to-hip ratioHealthy womenDisease risk factorsRisk factorsCancer Prevention TrialAssociated with venous thrombosisFactor VII coagulant activityAssociation of tamoxifenFactors related to inflammationEffects of oral tamoxifenCardiac risk factorsC-reactive proteinVII coagulant activitySecondary analysisPrevention trialsMedian fibrinogenOral tamoxifenPostmenopausal womenPostmenopausal estrogenVenous thrombosis
1995
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group.
Tilley B, Alarcon G, Heyse S, Trentham D, Neuner R, Kaplan†D, Clegg D, Leisen J, Buckley L, Cooper S, Duncan H, Pillemer S, Tuttleman M, Fowler S. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Annals Of Internal Medicine 1995, 122: 81-9. PMID: 7993000, DOI: 10.7326/0003-4819-122-2-199501150-00001.Peer-Reviewed Original ResearchConceptsIgM rheumatoid factor levelsErythrocyte sedimentation rateRheumatoid factor levelsRheumatoid arthritisMinocycline groupGlobal assessmentPlacebo groupMore patientsPlatelet countModified Health Assessment QuestionnaireFactor levelsEfficacy of minocyclineEvaluator's global assessmentWeek 48 visitActive rheumatoid arthritisHealth Assessment QuestionnairePatient global assessmentPlacebo-controlled trialModerate rheumatoid arthritisDisease-modifying drugsMechanism of actionJoint tendernessMorning stiffnessStudy medicationDisease activity
1990
Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis.
Buckley L, Vacek P, Cooper S. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. The Journal Of Rheumatology 1990, 17: 1158-61. PMID: 2132565.Peer-Reviewed Original ResearchConceptsLow-dose methotrexateFolinic acidDose methotrexateRheumatoid arthritisShort-term side effectsDose of methotrexateIncidence of stomatitisFolinic acid supplementationTerm side effectsLeucovorin treatmentAntiarthritic effectsGastrointestinal toxicityMTX administrationCrossover trialTherapeutic effectAcid supplementationSide effectsMethotrexateLeucovorinArthritisSignificant differencesPatientsAdministrationDosePlacebo
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply